Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Pathology (Sydney)

• Publication date

  2011-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/PAT.0b013e328348a6e7PMID 21716157
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mucinous tumours of the ovary

  2011cited by this paper
• Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin

  2011cited by this paper
• Morphologic Spectrum of Immunohistochemically Characterized Clear Cell Carcinoma of the Ovary: A Study of 155 Cases

  2011influential reference
• Pathology and Genetics

  2010cited by this paper
• Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?

  2010cited by this paper
• Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas

  2010cited by this paper
• The pathology of and controversial aspects of ovarian borderline tumours

  2010cited by this paper
• Patterns of Low-grade Serous Carcinoma With Emphasis on the Nonepithelial-lined Spaces Pattern of Invasion and the Disorganized Orphan Papillae

  2010cited by this paper
• The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas

  2010cited by this paper
• Ovarian Intestinal Type Mucinous Borderline Tumors: Are We Ready for a Nomenclature Change?

  2010cited by this paper
• ARID1A mutations in endometriosis-associated ovarian carcinomas.

  2010cited by this paper
• Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases

  2010cited by this paper
• Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype

  2010cited by this paper
• Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study

  2010cited by this paper
• Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

  2010cited by this paper
• The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis

  2010cited by this paper
• Lymph Node Metastasis in Grossly Apparent Stages I and II Epithelial Ovarian Cancer

  2009cited by this paper
• Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems

  2009cited by this paper
• A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary

  2009cited by this paper
• Anaplastic Carcinoma in Mucinous Ovarian Tumors: A Clinicopathologic Study of 34 Cases Emphasizing the Crucial Impact of Stage on Prognosis, Their Histologic Spectrum, and Overlap With Sarcomalike Mural Nodules

  2008influential reference
• A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

  2008cited by this paper
• Histologic subtypes of ovarian carcinoma: an overview.

  2008cited by this paper
• Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2

  2008cited by this paper
• Ovarian Clear Cell Carcinoma With Papillary Features: A Potential Mimic of Serous Tumor of Low Malignant Potential

  2008cited by this paper
• Ovarian Mucinous Tumors Associated With Mature Cystic Teratomas: Morphologic and Immunohistochemical Analysis Identifies a Subset of Potential Teratomatous Origin That Shares Features of Lower Gastrointestinal Tract Mucinous Tumors More Commonly Encountered as Secondary Tumors in the Ovary

  2007cited by this paper
• Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship

  2007cited by this paper
• The Development of High-grade Serous Carcinoma From Atypical Proliferative (Borderline) Serous Tumors and Low-grade Micropapillary Serous Carcinoma: A Morphologic and Molecular Genetic Analysis

  2007cited by this paper
• A candidate precursor to serous carcinoma that originates in the distal fallopian tube (J Pathol 2007; 211: 26–35)

  2007cited by this paper
• Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium.

  2007cited by this paper
• Undifferentiated carcinoma of the endometrium: a review.

  2007cited by this paper
• Interobserver and Intraobserver Variability of a Two-tier System for Grading Ovarian Serous Carcinoma

  2007cited by this paper
• An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma

  2007cited by this paper
• High‐grade ovarian serous carcinoma exhibits significantly higher p16 expression than low‐grade serous carcinoma and serous borderline tumour

  2007cited by this paper
• My approach to and thoughts on the typing of ovarian carcinomas

  2007cited by this paper
• Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases

  2006cited by this paper
• Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7

  2006cited by this paper
• Ovarian Atypical Proliferative (Borderline) Mucinous Tumors: Gastrointestinal and Seromucinous (Endocervical-Like) Types are Immunophenotypically Distinctive

  2006cited by this paper
• The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome

  2006cited by this paper
• Advances in the Recognition of Tubal Intraepithelial Carcinoma: Applications to Cancer Screening and the Pathogenesis of Ovarian Cancer

  2006cited by this paper
• Ovarian clear cell adenocarcinoma: a continuing enigma

  2006cited by this paper
• Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data.

  2006cited by this paper
• Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary

  2006cited by this paper
• Cytokeratins 7 and 20 in Primary and Secondary Mucinous Tumors of the Ovary: Analysis of Coordinate Immunohistochemical Expression Profiles and Staining Distribution in 179 Cases

  2006cited by this paper
• Ovarian Involvement by Metastatic Colorectal Adenocarcinoma: Still a Diagnostic Challenge

  2006cited by this paper
• Distinct Molecular Alterations in Complex Endometrial Hyperplasia (CEH) With and Without Immature Squamous Metaplasia (Squamous Morules)

  2005cited by this paper
• Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features

  2005cited by this paper
• Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation

  2005cited by this paper
• An Immunohistochemical Comparison Between Low-Grade and High-Grade Ovarian Serous Carcinomas: Significantly Higher Expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in High-Grade Neoplasms

  2005cited by this paper
• Mucinous tumors of the ovary: a review.

  2005cited by this paper
• Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma

  2005cited by this paper
• WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract.

  2004cited by this paper
• In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours

  2004cited by this paper
• Utility of CDX-2 in Distinguishing Between Primary and Secondary (Intestinal) Mucinous Ovarian Carcinoma: An Immunohistochemical Comparison of 43 Cases

  2004cited by this paper
• Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors

  2004cited by this paper
• A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes

  2004cited by this paper
• Subclassification of Ovarian Surface Epithelial Tumors Based on Correlation of Histologic and Molecular Pathologic Data

  2004cited by this paper
• Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior.

  2004cited by this paper
• WT‐1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma

  2004cited by this paper
• Transitional Cell Carcinoma of the Ovary: A Morphologic Study of 100 Cases With Emphasis on Differential Diagnosis

  2004cited by this paper
• Grading Ovarian Serous Carcinoma Using a Two-Tier System

  2004influential reference
• Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

  2004cited by this paper
• The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin

  2004cited by this paper
• Endocervical-like Mucinous Borderline Tumors of the Ovary: A Clinicopathologic Analysis of 31 Cases

  2004cited by this paper
• Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.

  2004cited by this paper
• Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.

  2003cited by this paper
• Immunoprofile of Ovarian Tumors With Putative Transitional Cell (Urothelial) Differentiation Using Novel Urothelial Markers: Histogenetic and Diagnostic Implications

  2003cited by this paper
• The Distinction Between Primary and Metastatic Mucinous Carcinomas of the Ovary: Gross and Histologic Findings in 50 Cases

  2003cited by this paper
• Primary and Metastatic Mucinous Adenocarcinomas in the Ovaries: Incidence in Routine Practice With a New Approach to Improve Intraoperative Diagnosis

  2003cited by this paper
• CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours

  2003cited by this paper
• Mutational Analysis of K-ras Segregates Ovarian Serous Carcinomas into Two Types: Invasive MPSC (Low-grade Tumor) and Conventional Serous Carcinoma (High-grade Tumor)

  2003cited by this paper
• Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis.

  2003cited by this paper
• Symposium part 4: Should pathologists diagnose endocervical preneoplastic lesions "less than" adenocarcinoma in situ?: Counterpoint.

  2003cited by this paper
• Pathology and Genetics of Tumours of the Breast and Female Genital Organs

  2003cited by this paper
• Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas

  2002cited by this paper
• Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

  2002cited by this paper
• Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary.

  2002cited by this paper
• Morphological effects of chemotherapy on ovarian carcinoma.

  2002cited by this paper
• WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas.

  2002cited by this paper
• Diverse tumorigenic pathways in ovarian serous carcinoma.

  2002cited by this paper
• Malignancy in Endometriosis: Frequency and Comparison of Ovarian and Extraovarian Types

  2001cited by this paper
• Immunohistochemical Detection of the Wilms' Tumor Gene (WT1) in Epithelial Ovarian Tumors

  2000cited by this paper
• Histopathologic grading of ovarian carcinoma: a review and proposal.

  2000cited by this paper
• A Clinicopathologic Analysis of Atypical Proliferative (Borderline) Tumors and Well-Differentiated Endometrioid Adenocarcinomas of the Ovary

  2000cited by this paper
• Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach.

  1999cited by this paper
• Toward the development of a universal grading system for ovarian epithelial carcinoma

  1998cited by this paper
• Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system.

  1998cited by this paper
• Immunohistochemical Evidence Supporting the Appendiceal Origin of Pseudomyxoma Peritonei in Women

  1997cited by this paper
• K‐ras mutations in mucinous ovarian tumors

  1997cited by this paper
• Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma.

  1996cited by this paper
• Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma.

  1996cited by this paper
• Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.

  1996cited by this paper
• Expression of cytokeratin 7 in simultaneous mucinous tumors of the ovary and appendix.

  1995cited by this paper
• Endometrioid Carcinoma of the Ovary with a Prominent Spindle‐cell Component, a Source of Diagnostic Confusion A Report of 14 Cases

  1995cited by this paper
• Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei".

  1995cited by this paper
• Mural nodules in common epithelial tumors of the ovary.

  1994cited by this paper
• Observer disagreement in histological classification of ovarian tumors in Japan.

  1994cited by this paper
• Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer

  1992cited by this paper
• Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreatobiliary epithelial cells

  1992cited by this paper
• Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications

  1991cited by this paper
• Relative frequency of primary ovarian neoplasms: A 10‐year review

  1989cited by this paper

• Efficacy and Safety of Chemotherapy Combined with Hormonal Therapy in Heavily Pretreated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ELSA/KGOG3049): A Multicenter Pilot Study

  2025influential citation
• The Oncology Team of The Karlovac General Hospital Was the First in Croatia To Perform Ovarian Cancer Surgery Using the Latest ICG Technology-Case Report

  2025cites this paper
• Epithelial characteristics of ovarian clear cell carcinoma at single-cell resolution

  2025influential citation
• Biological characteristics of spontaneous ovarian cancer in Microtusfortis.

  2025cites this paper
• Controversies in the management of clear cell carcinoma of the uterus and ovary.

  2025cites this paper
• Prognostic factor analysis and nomogram construction for elderly patients with stages III and IV epithelial ovarian cancer: a study based on the SEER database

  2025cites this paper
• Clearer Horizons: The latest advances in clear cell ovarian cancer treatment.

  2025cites this paper
• Claudins in ovarian cancer: emerging biomarkers and therapeutic targets

  2025cites this paper
• Management of early-stage ovarian cancer: open questions and debated issues.

  2025cites this paper
• Role of DNA methylation and non‑coding RNAs expression in pathogenesis, detection, prognosis, and therapy‑resistant ovarian carcinoma (Review)

  2025cites this paper
• Genomics of ovarian cancers and the potential of precision medicine

  2025cites this paper
• Are there inequalities in ovarian cancer diagnosis and treatment in England? A population-based study.

  2025cites this paper
• Identification of DNA methylation based prognostic subtype and signature in epithelial ovarian cancer

  2025cites this paper
• Predicting Survival Outcomes for Patients with Ovarian Cancer Using National Cancer Registry Data from Taiwan: A Retrospective Cohort Study

  2025cites this paper
• Dynamic 3D microfluidic platform for exploring combined targeted therapy, chemotherapy, and virotherapy delivery in ovarian cancer.

  2025cites this paper
• Integration of cell-type resolved spatial proteomics and transcriptomics reveals novel mechanisms in early ovarian cancer

  2025cites this paper
• Survival of patients with 2014 FIGO stage IIIC high-grade serous ovarian cancer who were treated with platin-based adjuvant chemotherapy

  2025cites this paper
• Targeted radioiodine therapy of ovarian cancer via the sodium/iodide symporter (NIS).

  2025cites this paper
• Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments

  2025cites this paper
• Biomarkers in high grade serous ovarian cancer.

  2024cites this paper
• Appraisal of the causal effect of Chlamydia trachomatis infection on epithelial ovarian cancer risk: a two-sample Mendelian randomisation study

  2024cites this paper
• Squamous Cell Carcinoma of the Ovary: A Rare Case

  2024cites this paper
• The Influence of Circulating Immune Cell and CA125 Dynamics on Neoadjuvant Therapy Selection for Advanced Ovarian Cancer

  2024cites this paper
• Evaluating Ovarian Cancer Chemotherapy Response Using Gene Expression Data and Machine Learning

  2024cites this paper
• A Robust Deep Learning Framework for Ovarian Cancer Subtype Classification

  2024cites this paper
• Unveiling Commonalities: Exploring Shared Characteristics in Clear Cell Carcinomas of the Gynecologic Tract.

  2024cites this paper
• Pathology and Classification of Peritoneal Surface Malignancies.

  2024cites this paper
• Spatial profiling of ovarian clear cell carcinoma reveals immune-hot features.

  2024cites this paper
• Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas

  2024cites this paper
• Feasibility of iodine concentration parameter and extracellular volume fraction derived from dual-energy CT for distinguishing type I and type II epithelial ovarian carcinoma

  2024cites this paper
• Promising remission with reduced bevacizumab and pembrolizumab dosage in a patient with AT-rich interaction Domain 1A mutated ovarian clear-cell carcinoma refractory to chemotherapy

  2024cites this paper
• The multiple facets of ovarian high grade serous carcinoma: a review on morphological, immunohistochemical and molecular features.

  2024cites this paper
• Risk Factors Of Ovarian Cancer Among The Postmenopausal Women

  2024cites this paper
• Characterization of latently infected EBV+ antibody-secreting B cells isolated from ovarian tumors and malignant ascites

  2024cites this paper
• Effect of the Number of Negative Lymph Nodes Removed on the Survival and Recurrence Rate After Primary Surgery in Patients with Ovarian Cancer: A Multi-Center Retrospective Cohort Study

  2024cites this paper
• Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients

  2024cites this paper
• Human papillomavirus infection of the fallopian tube as a potential risk factor for epithelial ovarian cancer

  2024cites this paper
• Association of the Single Nucleotide Polymorphisms rs11556218, rs4778889, rs4072111, and rs1131445 of the Interleukin-16 Gene with Ovarian Cancer

  2024cites this paper
• Spatial profiling of ovarian clear cell carcinoma reveals immune-hot features

  2023cites this paper
• Targeting the immune microenvironment for ovarian cancer therapy

  2023cites this paper
• Advanced stage, high-grade primary tumor ovarian cancer: a multi-omics dissection and biomarker prediction process

  2023cites this paper
• Somatostatin and Somatostatin Receptors in Tumour Biology

  2023cites this paper
• A Clinical and Immunopathological Analysis of Carcinoma of the Ovary with an Emphasis on Post-chemotherapy Histopathologic Changes

  2023cites this paper
• Pattern of Care in Real-World Scenario on Advanced Epithelial Ovarian Cancer in a Tertiary Referral Oncology Centre in India — ISPSM Collaborative Study

  2023cites this paper
• Effect of tumor type on response to adjuvant platinum-based chemotherapy and prognosis in patients with stage II-IV epithelial ovarian carcinoma.

  2023cites this paper
• Integrated Multi-Omic Analysis Reveals Immunosuppressive Phenotype Associated with Poor Outcomes in High-Grade Serous Ovarian Cancer

  2023cites this paper
• Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer

  2023cites this paper
• Epithelial ovarian carcinoma – a perspective

  2023cites this paper
• SPON1 is an independent prognostic biomarker for ovarian cancer

  2023cites this paper
• HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.

  2023cites this paper
• BRCA Mutations—The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers

  2023cites this paper
• A pilot in vivo study: potential ovarian cancer therapeutic by placental extracellular vesicles

  2023cites this paper
• Ovarian Cancer—Insights into Platinum Resistance and Overcoming It

  2023cites this paper
• Molecular characteristics and clinical behaviour of epithelial ovarian cancers.

  2023cites this paper
• Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis

  2023cites this paper
• Effects of lysate/tissue storage at −80°C on subsequently extracted EVs of epithelial ovarian cancer tissue origins

  2023cites this paper
• Primary squamous cell carcinoma of the ovary accompanied by transition of a mucinous borderline ovarian tumor

  2023cites this paper
• The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response

  2022cites this paper
• BDP1 as a biomarker in serous ovarian cancer

  2022cites this paper
• The global, regional and national epidemiology, incidence, mortality, and burden of ovarian cancer

  2022cites this paper
• Use of asprosin and subfatin for differential diagnosis of serous ovarian tumors

  2022cites this paper
• Expression of DNA Methyltransferase 3B Isoforms Is Associated with DNA Satellite 2 Hypomethylation and Clinical Prognosis in Advanced High-Grade Serous Ovarian Carcinoma

  2022cites this paper
• Computed tomography–based radiomics machine learning classifiers to differentiate type I and type II epithelial ovarian cancers

  2022cites this paper
• Trends in the incidence of ovarian cancer in sub‐Saharan Africa

  2022cites this paper
• Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system

  2022cites this paper
• Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma

  2022cites this paper
• Rab11a promotes the malignant progression of ovarian cancer by inducing autophagy

  2022cites this paper
• Cytoreductive Surgery With or Without HIPEC in the Management of Peritoneal Dissemination from Rare Histological Subtypes of Ovarian Cancer — a Retrospective Study by INDEPSO

  2022cites this paper
• Clinical utility of pathology data: endometrial and tubo-ovarian carcinomas

  2022cites this paper
• An efficient deep equilibrium model for medical image segmentation

  2022cites this paper
• Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy

  2022cites this paper
• Impact of ovarian cancer on hormone imbalance and its remedies with ayurvedic medicines

  2022cites this paper
• A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.

  2022cites this paper
• Serum Free Fatty Acids and G-Coupled Protein Receptors Are Associated With the Prognosis of Epithelial Ovarian Cancer

  2022cites this paper
• Appendiceal tumors in patients undergoing primary surgery for mucinous ovarian tumors in a tertiary hospital, in Southern Thailand.

  2022cites this paper
• Differential Expression of Long Non-coding Ribonucleic Acid (RNA) Genes in Endometriosis-associated Ovarian Cancer (EAOC): A Pilot Meta-analysis for Pathological Insights and Potential Diagnostic Biomarker Identification

  2022cites this paper
• The Many Faces of Serous Neoplasms and Related Lesions of the Female Pelvis: A Review

  2022cites this paper
• Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma

  2022cites this paper
• A Study on P16 Expression in Surface Epithelial Tumours of Ovary

  2022cites this paper
• Shifting incidence and survival of epithelial ovarian cancer (1995‐2014): A SurvMark‐2 study

  2022cites this paper
• Suppression of the ABCA1 Cholesterol Transporter Impairs the Growth and Migration of Epithelial Ovarian Cancer

  2022cites this paper
• Iatrogenic Leptomeningeal Carcinomatosis Following Craniotomy for Resection of Metastatic Serous Ovarian Carcinoma: A Systematic Literature Review and Case Report

  2022cites this paper
• The role of the inflammasome and its related pathways in ovarian cancer

  2022cites this paper
• A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models

  2022cites this paper
• Beta-glucans is a potential inhibitor of ovarian cancer: based on molecular and biological aspects.

  2021cites this paper
• Ovarian cancer: epigenetics, drug resistance, and progression

  2021cites this paper
• Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor

  2021cites this paper
• Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study

  2021cites this paper
• Connections between prolactin and ovarian cancer

  2021cites this paper
• Androgen/Androgen Receptor Signaling in Ovarian Cancer: Molecular Regulation and Therapeutic Potentials

  2021cites this paper
• Ovarian Cancer and Cancer Stem Cells—Cellular and Molecular Characteristics, Signaling Pathways, and Usefulness as a Diagnostic Tool in Medicine and Oncology

  2021cites this paper
• A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer

  2021cites this paper
• Resultados materno fetais de complicações na gestação com câncer de ovário

  2021cites this paper
• Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer

  2021cites this paper
• A Study of CD44 Positive Cancer Cells in Epithelial Ovarian Cancer and their Correlation with P53 And Ki67

  2021cites this paper
• Platinum-based Chemotherapy and Bevacizumab Instigate the Destruction of Human Ovarian Cancers via Different Signaling Pathways.

  2021cites this paper
• The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma.

  2021cites this paper
• Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways

  2021cites this paper
• Selection of Representative Histologic Slides in Interobserver Reproducibility Studies: Insights from Expert Review for Ovarian Carcinoma Subtype Classification

  2021cites this paper
• Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma

  2021cites this paper